SLC5A2 and type 2 diabetes mellitus: Recent renal outcome trails with agents such as thiazolidinediones, DPP-4 inhibitors, bardoxolone, and sulodexide have been unsuccessful; however, exciting new data from trials with GLP1R agonists and SGLT2 inhibitors show beneficial renal effects in patients with type 2 diabetes mellitus (T2DM) (8, 9).